Photo Dynamic Immuno Therapy (PDIT) is a novel approach for treatment of metastatic tumors. It involves an intratumor administration of a laser-absorbing dye and an immunoadjuvant, followed by a non-invasive laser irradiation. Previous studies using a novel immunoadjuvant, glycated chitosan, showed the effect of the treatment on a metastatic breast tumor in rats, including the eradication of treated primary tumors, regression of untreated metastases, and the evidence of immune responses induced by the treatment. To further understand the mechanism of PDIT, tumor-bearing rats were treated by different combinations of the three PDIT components. The rat survival rates and profiles of primary and metastatic tumors, after treatment by individual component and different combinations of components, were analyzed. All the experimental groups without using immunoadjuvant showed none or little positive effect. The use of glycated chitosan, either by itself or in combination of other components, has showed that among the concentrations of 0.5%, 1% and 2%, glycated chitosan was most effective at 1% in PDIT. Another immunoadjuvant, incomplete Freund's adjuvant, was also used and the results were compared with that of using glycated chitosan. PDIT was applied to a different tumor model- Met-Lu, a prostatic tumor with lung metastases in male rats and the preliminary results are reported.
|